Article Information
History
- September 22, 2018.
Article Versions
- Version 1 (February 16, 2018 - 21:45).
- You are currently viewing Version 2 of this article (September 22, 2018 - 13:43).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ron S. Gejman1,2,3,
- Heather F. Jones1,3,
- Martin G. Klat1,
- Aaron Y. Chang1,3,
- Claire Y. Oh1,3,
- Smita S. Chandran4,5,
- Tatiana Korontsvit1,
- Viktoriya Zakahleva1,
- Tao Dao1,
- Christopher A. Klebanoff3,4,5 and
- David A. Scheinberg1,3,5
- 1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10065
- 2Tri-Institutional MD-PhD Program (MSKCC, Rockefeller University, Weill Cornell Medical College), New York, NY, USA. 10065
- 3Weill Cornell Medicine, New York, NY, USA. 10065
- 4Center for Cell Engineering and Department of Medicine, MSKCC, New York, NY, USA. 10065
- 5Parker Institute for Cancer Immunotherapy, MSKCC, New York, NY, USA. 10065